Standalone Financial Results (Q1 FY27)

  • Revenue from operations: ₹26,051.71 lakhs (compared to ₹20,398.76 lakhs in Q1 FY26)
  • Other income: ₹1,309.64 lakhs
  • Total Income: ₹27,361.35 lakhs
  • Profit before tax: ₹8,220.96 lakhs (compared to ₹5,723.95 lakhs in Q1 FY26)
  • Profit after tax: ₹6,119.37 lakhs (compared to ₹4,256.55 lakhs in Q1 FY26)
  • Earnings per share (Basic and diluted): ₹5.85 (not annualized)
  • Total comprehensive income: ₹7,824.64 lakhs
  • Paid-up equity share capital: ₹1,046.16 lakhs (face value of ₹1 each)

Consolidated Financial Results (Q1 FY27)

  • Revenue from operations: ₹25,748.90 lakhs (compared to ₹20,398.76 lakhs in Q1 FY26)
  • Other income: ₹1,282.59 lakhs
  • Total Income: ₹27,031.49 lakhs
  • Profit before tax and share of profit of joint venture: ₹7,706.58 lakhs
  • Share of profit/(loss) of joint venture (net of tax): ₹127.73 lakhs
  • Profit before tax: ₹7,834.31 lakhs
  • Profit after tax: ₹5,769.69 lakhs (compared to ₹4,405.78 lakhs in Q1 FY26)
  • Earnings per share (Basic and diluted): ₹5.52 (not annualized)
  • Total comprehensive income: ₹7,475.83 lakhs
  • Profit attributable to owners: ₹5,852.62 lakhs

Subsidiary and Joint Venture Information

The consolidated results include:

  • Concord Lifegen Limited (wholly owned subsidiary)
  • Celliimune Biotech Private Limited (wholly owned subsidiary from April 02, 2026)
  • Stellon Biotech Inc. (subsidiary)
  • Concord Biotech Japan K.K. (joint venture)

The auditors noted that two subsidiaries with interim financial information reflecting total revenues of ₹26.86 lakhs and total net loss of ₹7.69 lakhs were reviewed by other auditors. One subsidiary with revenues of ₹7.59 lakhs and net loss of ₹331.73 lakhs, and one joint venture with net profit of ₹6.26 lakhs, were not reviewed but were considered immaterial to the Group.

Corporate Development

Celliimune Biotech Private Limited, incorporated on January 15, 2025, was acquired by Concord Biotech Limited effective April 02, 2026, and is now a wholly owned subsidiary.

Notes to Financial Results

The figures for the quarter ended March 31, 2026 are balancing figures between audited full-year figures and published year-to-date figures up to the third quarter ended December 31, 2025. The company operates in a single segment of manufacturing and trading pharmaceutical products as per Ind AS 108.

Auditor's Limited Review

BSR & Co. LLP issued limited review reports for both standalone and consolidated financial results, stating that nothing came to their attention causing them to believe that the statements contain any material misstatement or fail to disclose required information under Regulation 33 of Listing Regulations.